Showing 8421-8430 of 10255 results for "".
- Modernizing Medicine, Inc. Acquires Aesyntix Health, Inc.https://practicaldermatology.com/news/modernizing-medicine-inc-acquires-aesyntix-health-inc/2459037/Modermizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), completed an acquisition of Aesyntix Health, Inc. on
- Data for COMBI-v Study Now Publishedhttps://practicaldermatology.com/news/20141117-data_for_combi-v_study_now_published/2459059/Data demonstrating that treatment with the combination of trametinib (Mekinist™) and dabrafenib (Tafinlar™) significantly improved overall survival (OS) compared to vemurafenib monotherapy in previously untreated patients with BRAF V600E/K mutation-positive metastatic melanoma, without increased ov
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Study Finds that the Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanomahttps://practicaldermatology.com/news/20141024-study_finds_that_the_use_of_melafind_reduced_benign_biopsies_by_61_in_patients_at_risk_for_melanoma/2459079/The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observati
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the
- Syneron Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosishttps://practicaldermatology.com/news/20140815-syneron_introduces_new_fda-cleared_5mm_spot_size_for_treatment_of_onychomycosis/2459145/Syneron Medical Ltd. launched a new handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handp
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to Presi
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife